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Background: Hereditary spastic paraplegias (HSPs) are a group of neurodegenerative diseases characterized by
progressive spasticity and weakness of the lower limbs. SPG4, SPG3A and SPG31 are the three leading causes of
autosomal dominant (AD) HSPs.
Methods: A total of 20 unrelated AD-HSP families were recruited for clinical and genetic assessment. Detection of
mutations in SPG4, SPG3A and SPG31 genes was conducted according to a standard protocol. Genotype-phenotype
correlations and determinants for disease severity and progression were analyzed.
Results: Mutations in the SPG4 gene (SPAST) were detected in 18 (90%) of the AD-HSP families. Mutations in SPG4,
SPG3A and SPG31 genes were not detected in the remaining two families. Considerable variations in clinical features
were noted, even for mutation carriers from the same family. Mutations causing complete loss of the spastin AAA
cassette were associated with earlier onset of disease (20 ± 18 years) compared with those with preservation of partial
or total AAA cassette (32 ± 19 years, p = 0.041). For those with SPG4 mutations, disease severity was related to the
patients’ current age, and the progression rate of disease was positively correlated with age at onset.
Conclusions: SPG4 accounts for most of the AD-HSP cases in Taiwanese, with a frequency significantly higher than in
other populations. SPAST mutations which predict complete loss of the spastin AAA cassette were associated with an
earlier onset of disease.
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Hereditary spastic paraplegias (HSPs) are a heterogeneous
group of neurodegenerative disorders clinically character-
ized by progressive spasticity and weakness of the lower
limbs [1]. They can be classified according to the mode of
inheritance, or by the absence (“pure form”) or presence
(“complicated form”) of additional neurological or systemic
manifestations such as dementia, epilepsy, mental retard-
ation, thin corpus callosum, cerebellar ataxia, peripheral
neuropathy, deafness, retinopathy, and optic atrophy [1,2].* Correspondence: bob.cslu@gmail.com
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unless otherwise stated.Pure forms of HSPs are usually inherited as an autosomal
dominant trait, whereas most complicated HSPs are auto-
somal recessive forms. To date, more than 70 loci for
HSPs have been mapped and at least 55 genes have been
identified [3].
Autosomal dominant HSPs (AD-HSPs) represent
around 70% of cases of uncomplicated HSPs [4]. SPG4 is
the most common form of AD-HSP, accounting for
around 40% of the families in previous reports [2,5]. Spas-
tin, the protein encoded by the SPG4 gene, is a member of
the family of AAA proteins (ATPase associated with di-
verse cellular activities) which share a common functional
domain called the AAA cassette [6]. SPG3A is the second
most frequent form of AD-HSP, representing approxi-
mately 7-10% of all AD-HSP families [7,8]. The SPG3A
gene encodes the protein atlastin-1 which is structurally. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Lan et al. BMC Neurology 2014, 14:216 Page 2 of 7
http://www.biomedcentral.com/1471-2377/14/216homologous to members in the dynamin superfamily of
GTPases [9]. SPG31 has been suggested to be the third
most common cause of AD-HSP, with an overall fre-
quency of 2.3-6.5% in the kindreds of primarily European
descent [10,11]. The SPG31 gene encodes receptor
expression-enhancing protein 1 which may be involved in
a chaperone-like function [10].
We previously reported four Taiwanese families with
SPG4-related HSP [12]. In this study, we extended the
scope of the investigation to screen SPG4, SPG3A and
SPG31 in additional AD-HSP families. The results showed
an unexpectedly high frequency of SPG4 in the cohort of
Taiwanese AD-HSP families.
Methods
The study protocol was approved by the Chang Gung
Memorial Hospital Institutional Review Board (No. 100-
4460C). Clinical and genetic features of the participants
were examined after written informed consent had been
obtained from participants or a parent while participants
were children.
Patients and clinical examinations
This study included 20 unrelated AD-HSP kindreds (49
cases in total) of Han Taiwanese ethnicity collected from
the Departments of Neurology, Rehabilitation and
Pediatric, Chang Gung Memorial Hospitals, Taiwan
(Additional file 1: Figure S1). Families 1 to 4 have been
reported previously [12]. A diagnosis of AD-HSP was
based on the following diagnostic criteria: (1) spastic
paraplegia, or (2) spastic tetraparesis with earlier and
more severe affliction of the lower limbs, or (3) spastic
paraplegia as an early and prominent sign of a degenera-
tive disease affecting the nervous system; (4) positive
family history of spastic paraplegia with affected mem-
bers in at least two generations; and (5) no other causes
of the presenting symptoms [4]. Family history was re-
corded according to the patients’ reports, and inherit-
ance was ascertained in 14 families by examining
affected family members. Clinical information was col-
lected and neurological examinations were performed.
Ambulatory disability was scored based on a five-point
scale: 0 asymptomatic, 1 minimally impaired (able to
run), 2 mildly impaired (able to walk independently but
not run), 3 moderately impaired (walk with an aid), and
4 severely impaired (wheelchair bound).
Genetic studies
Genomic DNA was extracted from peripheral blood leu-
kocytes for genetic analysis, and mutation screenings
were conducted in the following order. First, nucleotide
substitutions and small deletions or insertions in all
exons and their adjacent splicing sites of the SPG4 gene
(SPAST) were analyzed by polymerase chain reactionsand direct sequencing. If a mutation was not detected,
multiplex ligation-dependent probe amplification (MLPA)
was performed to detect exonic deletions in SPAST. Fi-
nally, for the cases with no detected mutations in SPAST,
sequence analysis and MLPA of the SPG3A gene (ATL1)
and sequence analysis of the SPG31 gene (REEP1) were
performed. Detected mutations were checked in 100 con-
trol DNA samples collected from unrelated ethnic Han
Taiwanese.
MLPA was performed using SALSA MLPA kits (P165-B1
HSP probemix; MRC-Holland, Amsterdam, Netherlands)
according to the manufacturer’s instructions. For each sam-
ple, a normalized value ratio for a relative peak area be-
tween 0.8 and 1.2 was considered normal. A heterozygous
deletion was expected with a ratio between 0.3 and 0.7, and
a heterozygous duplication between 1.3 and 1.7. Total
mRNA from the blood leukocytes was extracted using Tri-
zol procedure (Invitrogen, Carlsbad, CA, United States).
mRNA analysis was performed as described previously [12]
to assess alternations in gene transcription due to SPAST
mutations.
Bioinformatic analysis
Novelty of a detected mutation was checked with the
Human Gene Mutation Database [13]. Amino acid con-
servation in orthologues was assessed using the Homo-
loGene database [14]. Prediction of pathogenicity of a
missense mutation was analysed using the PolyPhen-2
program [15].
Statistical analysis
Data were presented as mean ± SD unless otherwise spe-
cified. Disease severity was defined as “mild” with an
ambulation score of 1 or 2, or “severe” with a score of 3
or 4. The progression rate of the disease was assessed
with a disease-progression score (DPS) calculated as the
current disability score divided by disease duration. Mu-
tations were classified according to the consequence,
namely, whether they caused a complete loss of the
AAA cassette (i.e. nonsense and frameshift mutations
proximal to the encoding sequence of the AAA cassette,
whole gene deletion, and mRNA decay) or not. Age at
onset (AAO) with respect to mutation consequence was
tested with t-tests (asymptomatic cases were excluded
from the analysis). The relationships between disease se-
verity and current age, gender, disease duration and mu-
tation consequence were tested using the chi-square test
or t-test. The relationships between DPS and AAO, gen-
der and mutation consequence were tested using the
Pearson test or t-test. Independence of the association
between disease severity (or DPS) and clinical and gen-
etic factors was examined using logistic (or linear) re-
gression analysis. A p value <0.05 was considered to be
statistically significant.
Table 1 Summary of the families in the current study




DPS SPAST mutation Mutation location Presumed effect
of the mutation
1‡ F 6 2 2 0.50 c.1714_1715 del AT (p.M572VfsX3)§ Exon 16 Protein truncation
F* 4 2 2 1.00
2‡ F* 7 5 3 1.58 Deletion of 5′- region of exon
17 (p.M577DfsX16)
Exon 17 Protein truncation
F 4 2 2 0.74
M 1 1 1 2.00
3‡ M* 7 5 4 1.82 c.1382 T > C (p.L461P) Exon 11 Missense
M 6 6 2 4.00
M 6 5 3 3.00
M 4 - 0 0.00
F 3 3 1 3.33
M 3 2 3 5.00
F 3 - 0 0.00
4‡ F 8 6 4 1.90 Deletion of exon 17 Exon 17 Protein truncation?
M* 6 5 3 3.75
F 5 5 2 5.00
5 M* 7 2 3 0.70 Deletion of the whole gene Exon 1-17 No mRNA production
6 M 5 - 0 0 c.1361_1363 ins GGG✰ Exon 11 mRNA decay
M* 2 1 1 1.00
M 1 1 1 1.67
7 F* 6 5 2 1.82 c.1714_1715 del AT (p.M572VfsX3)§ Exon 16 Protein truncation
M 4 1 2 0.67
F 5 1 1 0.29
M 2 1 1 0.83
M 5 2 2 0.57
8 F* 6 5 3 3.00 c.1684 C > T (p.R562X) Exon 15 Protein truncation
9 M 4 3 3 2.31 c.1005-1 G > C (p.N335NfsX2)✰ Intron 6 Protein truncation
F 1 1 1 2.00
M* 1 1 1 2.00
10 F 8 4 1 0.28 c.1004 + 1 G > T (p.G291WfsX4)✰ Intron 6 Protein truncation
M 6 1 1 0.24
F* 5 2 1 0.34
M 1 1 2 2.86
11 F* 5 4 2 2.00 c.1738_1740 del ATT/ins GA
(p.I580DfsX9)¶✰
Exon 17 Protein truncation
12 M* 6 4 3 1.50 c.1664 A > G (p.D555G) Exon 15 Missense
13 F 7 6 3 2.00 c.448_451 del AAGA (p.K150KfsX9) Exon 2 Protein truncation
M* 5 1 3 0.77
14 M* 6 5 2 5.00 Not detected Not applicable
15 F 8 7 3 6.00 c.1741 C > T (p.R581X)∥ Exon 17 Protein truncation
M* 6 5 2 1.54
M 5 5 1 2.00
16 F 7 5 3 1.58 c.730 ins T, c.732_733 ins
CA (p.N244X)#
Exon 5 Protein truncation
M* 6 5 3 2.50
17 F 7 7 2 4.00 c.1741 C > T (p.R581X)∥ Exon 17 Protein truncation
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Table 1 Summary of the families in the current study (Continued)
M* 5 3 3 2.31
18 M* 7 3 2 0.54 c.730 ins T, c.732_733 ins
CA (p.N244X)#
Exon 5 Protein truncation
M 6 4 3 1.88
19 M* 3 2 1 1.67 Not detected Not applicable
20 F 6 5 3 3.33 c.1738_1740 del ATT/ins
GA (p.I580DfsX9)¶✰
Exon 17 Protein truncation
M 6 4 2 1.54
Abbreviations: DPS disease progression score, F female, M male.
*proband.
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Mutation detection
A total of 14 different SPAST mutations were identified
in 18 families (Table 1). In this cohort, SPG4 accounted
for 90% of the AD-HSP families. Mutation types were
quite heterogeneous, including nonsense (2), missense
(2), insertion (2), deletion (2), insertion-deletion (1),
splicing site (2), and large exonic deletion (3) (Figure 1).
Four mutations (c.1361_1363 ins GGG, c.1005-1 G > C,
c.1004 + 1 G > T, and c.1738_1740 del ATT/ins GA)
were novel mutations. These mutations were neither in-
cluded in the data derived from the 1000 Genome Pro-
ject (http://www.1000genomes.org/) [16] nor detected
in the 100 control DNA samples. The residue leucine
affected by the missense mutation p.L461P and the resi-
due aspartate affected by D555G were highly evolution-
arily conserved according to the public genome database
(Additional file 2: Figure S2). The substitutions of aminoFigure 1 SPAST mutations detected in the current study. Schematic re
Numbered boxes indicate transcript coding regions in exons drawn to scalacids caused by the two missense mutations were pre-
dicted to be damaging (a score of 1.000 and 0.988 respect-
ively) by the PolyPhen-2 program. In general, nonsense
and missense mutations were located in the 3′ half of
SPAST exons, while frameshift (mini-insertions and mini-
deletions) and splicing site mutations were more evenly
distributed in the gene. Co-segregation of mutations with
the disease was confirmed in 14 families, in which at least
two affected members underwent genetic testing. Muta-
tions in SPAST, ATL1 and REEP1 were not detected in
two families (Families 14 and 19).
SPAST mRNA analysis
For the in-frame insertion c.1361_1363 ins GGG de-
tected in Family 6, only the wild type of mRNA was de-
tected in mRNA analysis and the decay of mutant
mRNA is suspected (Additional file 3: Figure S3). For
the other insertions and mutations of missense, nonsense,presentation of the location of SPAST mutations detected in this study.
e. Encoding region of the AAA cassette is highlighted.
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changes identical to those in genomic DNA. The two spli-
cing site mutations in intron 6 led to skipping of transcrip-
tion of the first 8 bases of exon 7 (Family 9) and the whole
of exon 6 (Family 10), respectively. For the exonic deletion
revealed by MLPA in Family 2, cDNA analysis showed a
deletion of 1090 bases at the 5′-end of exon 17, as re-
ported previously [12]. In Family 4, the effects of complete
loss of exon 17 on translation could not be determined
due to failure to amplify the mutant transcript.Clinical presentation
In this AD-HSP cohort, AAO in the probands ranged
from 1 to 48 years, and six (30%) families had at least
one case whose AAO was less than 10 years. The clinical
characteristics of the SPG4 cases are summarized in
Table 2. The onset of disease ranged from 1 to 69 years
of age. Among the 47 cases carrying SPAST mutations,
44 (94%) showed spastic paraparesis and 3 (6%) were
asymptomatic. All of the symptomatic SPG4 patients
manifested a pure phenotype, except for a case in Family
7 who presented with distal amyotrophy in the upper
limbs. The most common clinical presentation was gait
disorder due to spasticity or increased tendon reflexes in
the lower limbs. Neurological examinations of the cra-
nial nerves and upper limbs were normal except for an
accentuated jaw-jerk and tendon reflex in some patients.
Considerable variations in AAO, rate of progression or
severity of disease were noted, even in mutation carriers
from the same family (Table 1). There was no clear
phenotype correlation with respect to the different types
of mutations. For the two families without detectedTable 2 Clinical characteristics of the SPG4 patients (n = 47)
Men/Women 27/20
Mean age (range), years 44 ± 19 (6 – 74)
Mean age at onset (range), years* 28 ± 19 (1 – 69)
Mean disease duration (range), years* 17 ± 12 (3 – 43)
Clinical features
Asymptomatic individuals 3/47 (6%)
Increased tendon reflexes in the upper limbs 40/47 (85%)
Increased tendon reflexes in the lower limbs 47/47 (100%)
Presence of extensor plantar reflex 29/45 (64%)
Presence of ankle clonus 23/42 (55%)
Attenuated vibration perception at the ankles 23/45 (51%)
Dysfunction of bladder control† 21/46 (46%)
Ambulation function, 0/1/2/3/4 3/12/14/16/2
case No. (%)‡ (6%/26%/30%/34%/4%)
*asymptomatic cases not included.
†urinary retention, frequency or incontinence.
‡0, asymptomatic; 1, able to run; 2, unable to run, walking independently;
3, walking with an aid; 4, wheelchair bound.mutations, one had a pure phenotype while the other
presented with deafness in the affected members.
Phenotype determinants
For the SPG4 cases, mutations causing complete loss of
the AAA cassette were associated with an earlier onset of
disease (20 ± 18 years, n =16) compared with those with
preservation of partial or total AAA cassette (32 ± 19 years,
n = 28; p = 0.041). In univariate analysis, disease severity
was related with the patients’ current age (37 ± 19 years
for mild disease vs. 55 ± 12 years for severe disease,
p <0.001), and DPS was correlated with AAO (r = 0.564,
p <0.001) (Additional file 4: Table S1 and Additional file 5:
Table S2). After adjusting for gender, disease duration and
consequence of mutation, the association of age (odds ra-
tio 1.10, 95% confidence interval 1.04-1.16 for every in-
crease of 1 year, p = 0.002) with disease severity, and that
of AAO (β = 0.038, standard error 0.010, p <0.001) with
DPS remained significant. Consequence of SPAST muta-
tion was not related with either disease severity or DPS.
Discussion
Compared to previous series in other populations, the
current findings showed a significantly higher frequency
of SPG4 for AD-HSP in our ethnically Han Taiwanese
cohort (90% vs. 30-60%; Additional file 6: Table S3). Pre-
viously, a study of HSP cohort in Sardinia, Italy showed
that SPG4 was responsible for all of nine AD-HSP fam-
ilies receiving genetic test [17]. However, eight of these
SPG4 families were attributable to a same multi-exonic
deletion in SPAST, suggesting a founder effect for this
mutation in this population. In contrast, the predomin-
ance of SPG4 in our cohort could not be due to specific
founder mutations because most of the detected muta-
tions were unique to the respective families. Although 7-
10% of AD-HSPs are known to be caused by SPG3A,
none of our cases had ATL1 mutations. SPG3A is char-
acterized by early onset of disease, usually before 10 years
of age [8]. Failure to detect SPG3A in this study due to
ascertainment bias is unlikely in view of the wide range
of AAO (1–48 years) in the probands and the inclusion
of pediatric cases in this cohort. A possible explanation
for this phenomenon may be ethnic differences in the
genetic background. However, because of the relatively
small kindred number in the present study, this finding
needs to be confirmed with a larger cohort of AD-HSP
families.
The current study showed that missense mutations
were located in the AAA cassette-encoding region,
while frameshift mutations which create premature ter-
mination codons were scattered along the SPAST gene
(Figure 1). In spite of the heterogeneity in mutation
types, all of these mutations may either alter the struc-
ture or disrupt the integrity of the AAA cassette.
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duce a truncated spastin or absence of mRNA transcrip-
tion. This finding suggests that haploinsufficiency due
to the abolishment of ATPase activity is the most
important pathogenicity for disease-causing SPAST
mutations.
For SPG4, mutations causing a complete loss of the
spastin AAA cassette were associated with earlier onset
of disease than those with at least partial AAA cassette
preservation. However, further studies of the production
of truncated spastin proteins by the mutations predict-
ing partial AAA loss and function of spastin protein car-
rying partial AAA cassette in cellular levels will be
needed to provide biological evidence for this finding.
Except for the common motor dysfunction due to spas-
tic paraparesis, remarkable variations in onset age, pro-
gression rate and disease severity were noted in the
SPG4 patients, even for those from the same family. We
also found that later onset of the disease was associated
with faster disease progression. This finding is consist-
ent with Harding’s observation on the pure form AD-
HSP [18] and has also been noted in previous studies in
SPG4 [19,20]. In addition, the patient’s current age was
the most significant determinant for disease severity.
Taken together, these findings suggest that the SPG4
phenotype is the product of interactions between SPAST
mutations and environmental or other genetic factors.
There are some limitations to this study. First, this
study was based on a relatively small cohort of AD-HSP
kindreds collected from two medical centers in Taiwan.
Our findings need to be confirmed by a more extensive
nationwide survey of AD-HSP families. Second, this is a
cross-sectional study, and disease progression would be
more accurately evaluated by a longitudinal observation.
Third, the five-graded ambulation score did not have
enough sensitivity in detecting minor differences in dis-
ease severity. A more detailed assessment scale, such as
Spastic Paraplegia Rating Scale [21], would be better in
reflecting overall functional impairment. Fourth, because
the age of symptom onset was determined according to
patient reports, there could be errors in recalling the in-
formation, especially for those with long-lasting disease.
Finally, this study did not test the genetic modifiers,
such as some sequence variants in ATL1 and HSPD1,
which have been postulated to account for the variability
in SPG4 phenotypes [22].
Conclusions
SPG4 accounted for a significantly higher proportion of
AD-HSPs in ethnic Taiwanese than in other populations.
There was no clear genotype-phenotype correlation
among the SPG4 patients, except that mutations result-
ing in complete loss of the spastin AAA cassette were
associated with an earlier onset of disease.Additional files
Additional file 1: Figure S1. Pedigrees of the 20 HSP families in the
study. The pedigrees of the 20 hereditary spastic paraplegia families
included in the study. The circles represent female subjects and the
squares represent male subjects, and the diamond represents the patient
whose gender was withheld for confidentiality reasons. The filled
symbols indicate affected individuals and the question marks indicate
uncertain disease affection. The cases that were involved in the clinical
and genetic studies are indicated with a cross bar above the individual
symbol. The probands are indicated by arrows.
Additional file 2: Figure S2. Conservation of the mutated residues in
different species. Conservation of the residues affected by the mutations
p.L461P and p.D555G in different species.
Additional file 3: Figure S3. cDNA analysis of the mutations. cDNA
analysis of the SPAST mutations in Family 2 (large deletion of 5′ region of
exon 17), Family 9 (spicing acceptor mutation, the boxed sequence
representing the nucleotides spliced during transcription due to the
mutation) and Family 10 (splicing donor mutation).
Additional file 4: Table S1. Determinants of SPG4 disease severity.
Univariate and multivariate regression analyses for determinants of
disease severity in the SPG4 cases.
Additional file 5: Table S2. Determinants of SPG4 disease progression.
Univariate and multivariate analyses for determinants of disease
progression score in the SPG4 cases.
Additional file 6: Table S3. Proportions of SPG4 in different
populations. Proportions of SPG4 in autosomal dominant hereditary
spastic paraplegias (AD-HSPs) in different populations.
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